Table 3.
Effect of 7-HC, Cisplatin and their combination on human cancer cell survival.
| Treatment (μg/ml) | Cell Lines (% survival) | |||||||
|---|---|---|---|---|---|---|---|---|
| SF-268 | Caco-2 | HT-29 | Sk-OV-3 | |||||
| 24 h | 48 h | 24 h | 48 h | 24 h | 48 h | 24 h | 48 h | |
| Cis (2.5) | 90.1 ± 4.6 | 73.0 ± 1.5 | 89.8 ± 4.4 | 87.9 ± 3.1 | 92.6 ± 3.6 | 89.7 ± 2.8 | 97.9 ± 1.9 | 93.7 ± 1.7 |
| Cis (5) | 79.0 ± 4.8 | 61.7 ± 3.3 | 68.3 ± 1.9 | 50.1 ± 2.9 | 88.9 ± 3.4 | 88.7 ± 2.3 | 95.6 ± 2.2 | 91.7 ± 1.8 |
| 7-HC (5) | 86.2 ± 2.9 | 80.1 ± 2.1 | 85.1 ± 4.1 | 87.3 ± 3.2 | 86.8 ± 3.7 | 89.6 ± 2.7 | 97.2 ± 2.8 | 99.1 ± 2.5 |
| 7-HC (10) | 43.7 ± 2.5 | 36.8 ± 2.4 | 49.7 ± 3.8 | 49.2 ± 3.4 | 46.5 ± 4.1 | 54.3 ± 3.0 | 97.4 ± 3.2 | 97.3 ± 2.3 |
| Cis (2.5) + 7-HC (5) | 81.4 ± 2.4 | 57.3 ± 1.8a,b | 78.4 ± 2.1 | 74.6 ± 3.9 | 79.9 ± 2.5 | 82.2 ± 3.9 | 95.6 ± 1.5 | 89.4 ± 3.2 |
| Cis (2.5) + 7-HC (10) | 35.3 ± 2.3a | 12.4 ± 3.9a,b | 41.2 ± 2.5a | 36.4 ± 2.8a | 35.6 ± 3.9a | 44.1 ± 2.8a,b | 93.9 ± 2.5 | 88.4 ± 4.1 |
| Cis (5) + 7-HC (5) | 66.3 ± 3.2a,b | 44.1 ± 2.9a,b | 59.3 ± 4.3b | 50.9 ± 3.1b | 76.2 ± 2.8a | 78.9 ± 3.8 | 94.0 ± 1.8 | 86.7 ± 2.6 |
| Cis (5) + 7-HC (10) | 26.7 ± 1.9a,b | 7.7 ± 1.3a,b | 27.1 ± 2.6a,b | 23.4 ± 3.9a,b | 36.6 ± 2.2a | 40.1 ± 3.5a,b | 92.8 ± 2.7 | 87.7 ± 2.8 |
The values are expressed as mean ± SEM from three independent experiments. Means with superscripts ‘a’ and/or ‘b’ are significantly (p < 0.05) different compared to similar doses of Cisplatin and/or 7-HC respectively.